Cargando…
Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
PURPOSE: Diabetic macular edema (DME) is a vision-threatening condition that develops in diabetic patients. The first-line therapy for DME is intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents; however, the high frequency of repeat injections, invasiveness of the pr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683151/ https://www.ncbi.nlm.nih.gov/pubmed/33274092 http://dx.doi.org/10.1155/2020/8867079 |
_version_ | 1783612817657561088 |
---|---|
author | Takatsuna, Yoko Ishibashi, Ryoichi Tatsumi, Tomoaki Koshizaka, Masaya Baba, Takayuki Yamamoto, Shuichi Yokote, Koutaro |
author_facet | Takatsuna, Yoko Ishibashi, Ryoichi Tatsumi, Tomoaki Koshizaka, Masaya Baba, Takayuki Yamamoto, Shuichi Yokote, Koutaro |
author_sort | Takatsuna, Yoko |
collection | PubMed |
description | PURPOSE: Diabetic macular edema (DME) is a vision-threatening condition that develops in diabetic patients. The first-line therapy for DME is intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents; however, the high frequency of repeat injections, invasiveness of the procedure, and high cost are drawbacks for this treatment. The purpose of this report is to present our findings in 3 patients with chronic DME whose edema was resolved soon after oral doses of sodium-glucose cotransporter-2 (SGLT2) inhibitors were used. Case Presentation. Case 1 was a 66-year-old woman diagnosed with moderate nonproliferative diabetic retinopathy (DR) with DME that had developed a decade earlier. The DME persisted for 4 years in the left eye. The addition of oral empagliflozin, a SGLT2 inhibitor, led to a marked improvement of the DME after one month, and this improvement continued over two years. Case 2 was a 68-year-old woman who was diagnosed with preproliferative DR with bilateral DME. The addition of oral dapagliflozin led to the improvement of the DME after two months, and this improvement continued over one year. Case 3 was a 61-year-old woman who was diagnosed with moderate nonproliferative DR with DME. Oral luseogliflozin was given which led to better glycemic control, and her left central retinal thickness (CRT) was markedly reduced after only two weeks. This reduction was maintained in her left eye for six months without any additional ophthalmic procedures. CONCLUSIONS: Although this study involved only three cases, our findings indicate that SGLT2 inhibitors might have possible efficacy for chronic DME. |
format | Online Article Text |
id | pubmed-7683151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-76831512020-12-02 Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema Takatsuna, Yoko Ishibashi, Ryoichi Tatsumi, Tomoaki Koshizaka, Masaya Baba, Takayuki Yamamoto, Shuichi Yokote, Koutaro Case Rep Ophthalmol Med Case Report PURPOSE: Diabetic macular edema (DME) is a vision-threatening condition that develops in diabetic patients. The first-line therapy for DME is intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents; however, the high frequency of repeat injections, invasiveness of the procedure, and high cost are drawbacks for this treatment. The purpose of this report is to present our findings in 3 patients with chronic DME whose edema was resolved soon after oral doses of sodium-glucose cotransporter-2 (SGLT2) inhibitors were used. Case Presentation. Case 1 was a 66-year-old woman diagnosed with moderate nonproliferative diabetic retinopathy (DR) with DME that had developed a decade earlier. The DME persisted for 4 years in the left eye. The addition of oral empagliflozin, a SGLT2 inhibitor, led to a marked improvement of the DME after one month, and this improvement continued over two years. Case 2 was a 68-year-old woman who was diagnosed with preproliferative DR with bilateral DME. The addition of oral dapagliflozin led to the improvement of the DME after two months, and this improvement continued over one year. Case 3 was a 61-year-old woman who was diagnosed with moderate nonproliferative DR with DME. Oral luseogliflozin was given which led to better glycemic control, and her left central retinal thickness (CRT) was markedly reduced after only two weeks. This reduction was maintained in her left eye for six months without any additional ophthalmic procedures. CONCLUSIONS: Although this study involved only three cases, our findings indicate that SGLT2 inhibitors might have possible efficacy for chronic DME. Hindawi 2020-11-12 /pmc/articles/PMC7683151/ /pubmed/33274092 http://dx.doi.org/10.1155/2020/8867079 Text en Copyright © 2020 Yoko Takatsuna et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Takatsuna, Yoko Ishibashi, Ryoichi Tatsumi, Tomoaki Koshizaka, Masaya Baba, Takayuki Yamamoto, Shuichi Yokote, Koutaro Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema |
title | Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema |
title_full | Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema |
title_fullStr | Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema |
title_full_unstemmed | Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema |
title_short | Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema |
title_sort | sodium-glucose cotransporter 2 inhibitors improve chronic diabetic macular edema |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683151/ https://www.ncbi.nlm.nih.gov/pubmed/33274092 http://dx.doi.org/10.1155/2020/8867079 |
work_keys_str_mv | AT takatsunayoko sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema AT ishibashiryoichi sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema AT tatsumitomoaki sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema AT koshizakamasaya sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema AT babatakayuki sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema AT yamamotoshuichi sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema AT yokotekoutaro sodiumglucosecotransporter2inhibitorsimprovechronicdiabeticmacularedema |